Results 211 to 220 of about 9,104,531 (349)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Sociability and whole-brain resting-state connectivity. [PDF]

Sci Rep
Rovný M, Sprooten E, Ilioska I, Fanelli G, Marquand AF, Fabbri C, Kas MJH, Serretti A, Franke B.   +8 more
europepmc   +1 more source

Association Affairs [PDF]

IAWA Journal, 1985
openaire   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Aberrant CD4 expression in plasmablastic transformation of multiple myeloma

eJHaem
Kohei Shiroshita, Sumiko Kohashi, Miki Sakamoto, Himari Kudo, Kuniaki Nakanishi, Takaaki Toyama   +5 more
doaj   +1 more source

Deep Learning for Analysis of Bone Marrow Adiposity: Breakthroughs from Recent Large-Scale Analyses in the UK Biobank. [PDF]

Curr Osteoporos Rep
Xu W, Wang C, Cawthorn WP.
europepmc   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Systematic identification of trans eQTLs as putative drivers of known disease associations

Nature Genetics, 2013
H. Westra, M. Peters, T. Esko, H. Yaghootkar, C. Schurmann, J. Kettunen, M. Christiansen, B. Fairfax, K. Schramm, J. Powell, A. Zhernakova, D. Zhernakova, J. Veldink, L. H. van den Berg, J. Karjalainen, S. Withoff, A. Uitterlinden, A. Hofman, F. Rivadeneira, P. ’. ’t Hoen, E. Reinmaa, K. Fischer, M. Nelis, L. Milani, D. Melzer, L. Ferrucci, A. Singleton, D. Hernandez, M. Nalls, G. Homuth, M. Nauck, D. Radke, U. Völker, M. Perola, V. Salomaa, J. Brody, Astrid M. Suchy-Dicey, S. Gharib, D. Enquobahrie, T. Lumley, G. Montgomery, S. Makino, H. Prokisch, C. Herder, M. Roden, H. Grallert, T. Meitinger, K. Strauch, Yang Li, R. Jansen, P. Visscher, J. Knight, B. Psaty, S. Ripatti, A. Teumer, T. Frayling, A. Metspalu, J. V. van Meurs, L. Franke   +58 more
semanticscholar   +1 more source

Leveraging Large and Diverse Biobanks to Evaluate Gene-Disease Associations in Hypertrophic Cardiomyopathy. [PDF]

J Pers Med
Dababneh SF, Ong K, Yeung D, Hawkins NM, Krahn A, Laksman Z, Tadros R, Roston TM.   +7 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source